November 16, 2022
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses faricimab (Vabysmo) 6 mg (6 mg per 0.05 mL of solution) for intravitreal injection.
- Indication: Neovascular (wet) age-related macular degeneration (proposed).